Endocrinol Metab.  2021 Dec;36(6):1307-1311. 10.3803/EnM.2021.1190.

Outcomes and Predictors of 30-Day Readmissions for Hyperthyroidism: A Nationwide Study

• Salim M
• El-amir Z
• Kichloo A
• Wani F
• Edigin E
• Shaka H

• KMID: 2523499
• DOI: http://doi.org/10.3803/EnM.2021.1190

Abstract

Hyperthyroidism is associated with an elevated risk of cardiovascular events and worse hospital outcomes. The Nationwide Readmissions Database (NRD) 2018 was used to determine the characteristics of 30-day readmission in patients with hyperthyroidism. The 30-day all-cause readmission rate for hyperthyroidism was 10.3%. About 21.7% had hyperthyroidism as the principal diagnosis on readmission. Readmissions were associated with an increased odds of inpatient mortality (odds ratio, 7.04; 95% confidence interval [CI], 3.97 to 12.49), length of stay (5.2 days vs. 4.0 days; 95% CI, 0.7 to 1.8), total hospital charges, and cost of hospitalizations. Independent predictors of 30-day all-cause readmissions included Charlson Comorbidity Index ≥3 (adjusted hazard ratio [aHR], 1.76; 95% CI, 1.15 to 2.71), discharge against medical advice (aHR, 2.30; 95% CI, 1.50 to 3.53), protein-energy malnutrition (aHR, 1.54; 95% CI, 1.15 to 2.07), and atrial fibrillation (aHR, 1.41; 95% CI, 1.11 to 1.79). Aggressive but appropriate monitoring is warranted in patients with hyperthyroidism to prevent readmissions.

Keyword

Hyperthyroidism; Patient readmission; Hospital mortality

Reference

1. Bilal M, Abougergi MS, Tayyem O, Parupudi S, Rockey DC. Thirty-day readmission after esophageal variceal hemorrhage and its impact on outcomes in the United States. J Clin Gastroenterol. 2020; 54:477–83.

2. Boehme AK, Kulick ER, Canning M, Alvord T, Khaksari B, Omran S, et al. Infections increase the risk of 30-day readmissions among stroke survivors. Stroke. 2018; 49:2999–3005.

3. Galindo RJ, Hurtado CR, Pasquel FJ, Garcia Tome R, Peng L, Umpierrez GE. National trends in incidence, mortality, and clinical outcomes of patients hospitalized for thyrotoxicosis with and without thyroid storm in the United States, 2004–2013. Thyroid. 2019; 29:36–43.

4. Luo B, Yu Z, Li Y. Thyroid hormone disorders and sepsis. Biomed Mater Eng. 2017; 28(s1):S237–41.

5. Sundararajan V, Quan H, Halfon P, Fushimi K, Luthi JC, Burnand B, et al. Cross-national comparative performance of three versions of the ICD-10 Charlson index. Med Care. 2007; 45:1210–5.

6. Agency for Healthcare Research and Quality. HCUP user support (HCUP-US) [Internet]. Rockville: AHRQ;2021. [cited 2021 Nov 16]. Available from: https://www.hcup-us.ahrq.gov .

7. Hsieh LB, Yen TW, Dream S, Patel D, Evans DB, Wang TS. Perioperative management and outcomes of hyperthyroid patients unable to tolerate antithyroid drugs. World J Surg. 2020; 44:3770–7.

8. Pesce CE, Shiue Z, Tsai HL, Umbricht CB, Tufano RP, Dackiw AP, et al. Postoperative hypocalcemia after thyroidectomy for Graves’ disease. Thyroid. 2010; 20:1279–83.

9. Brito JP, Payne S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham LR, et al. Patterns of use, efficacy, and safety of treatment options for patients with Graves’ disease: a nationwide population-based study. Thyroid. 2020; 30:357–64.

10. Ryodi E, Metso S, Huhtala H, Valimaki M, Auvinen A, Jaatinen P. Cardiovascular morbidity and mortality after treatment of hyperthyroidism with either radioactive iodine or thyroidectomy. Thyroid. 2018; 28:1111–20.

11. Osuna PM, Udovcic M, Sharma MD. Hyperthyroidism and the heart. Methodist Debakey Cardiovasc J. 2017; 13:60–3.

12. Caulley L, Johnson-Obaseki S, Luo L, Javidnia H. Risk factors for postoperative complications in total thyroidectomy: a retrospective, risk-adjusted analysis from the National Surgical Quality Improvement Program. Medicine (Baltimore). 2017; 96:e5752.

13. Brandt F, Green A, Hegedus L, Brix TH. A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol. 2011; 165:491–7.

14. Costantino ME, Frey B, Hall B, Painter P. The influence of a postdischarge intervention on reducing hospital readmissions in a Medicare population. Popul Health Manag. 2013; 16:310–6.

15. Ojeda S, Anguita M, Delgado M, Atienza F, Rus C, Granados AL, et al. Short- and long-term results of a programme for the prevention of readmissions and mortality in patients with heart failure: are effects maintained after stopping the programme? Eur J Heart Fail. 2005; 7:921–6.